Chasing Pfizer, Sarepta Prepares To Launch Pivotal Duchenne Gene Therapy Trial

Investors Still Skeptical

 
• By Andrew McConaghie

Sarepta believes it is still very much in the running with its gene therapy but is playing down talk of an accelerated approval based on biomarker data.

Sarepta building
Sarepta already has three DMD products on the market, but analysts believe gene therapies are more likely to represent progress against the muscle-wasting disease. • Source: Alamy

More from Gene Therapies

More from Advanced Therapies